The China Lipid Lowering drug market size stood at around USD 5.01 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The Chinese market is the world’s most potential market for lipid-lowering drugs and one of the fastest-growing markets in the world. The market size of China’s lipid-lowering drugs will continue to expand, and the growth rate will gradually increase. China’s lipid-lowering drug industry structure imported drugs have long occupied a relatively high proportion of the market. The overall prevalence of dyslipidemia in Chinese adults is as high as 40.4%. The increase in the population’s serum cholesterol level will lead to an increase of approximately 9.2 million cardiovascular events from 2010 to 2030.
Growing prevalence of different cardiovascular diseases, which are caused by various factors such as increased obesity, changing food habits, higher alcohol consumption, and smoking is driving the cholesterol lowering drugs market. Some of the factors anticipated to boost the cholesterol lowering drug market growth are emergence of new drug classes, changes in lifestyles, lack of exercise, and increase in intake of saturated & trans-fat. New drug development therapies for cholesterol lowering and rising awareness about cardiovascular diseases are some of the major factors responsible for the growth of the cholesterol lowering drugs market. Lucrative opportunities in emerging economies are expected to provide significant prospects for the manufacturers in industry.